Hypoglycemics, Lantus Insulin

Similar documents
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

Sitagliptin (Januvia)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Combination Agents

Texas Prior Authorization Program Clinical Edit Criteria

Lidoderm (Lidocaine) Patch

Byetta (Exenatide Injection)

Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Anthem Blue Cross Life and Health Insurance Company are

Continuous Glucose Monitoring System

Victoza (Liraglutide) Solution for Injection

Glycated Hemoglobin/Glycated Protein

Continuous Glucose Monitoring System

Medical Policy An independent licensee of the Blue Cross Blue Shield Association.

Texas Prior Authorization Program Clinical Edit Criteria

Continuous Glucose Monitoring System

Amitiza (Lubiprostone)

Texas Prior Authorization Program Clinical Edit Criteria

Glucagon-Like Peptide (GLP-1) Receptor Agonists Clinical Edit Criteria

Therapeutic Shoes for Diabetics

Coding spotlight: diabetes provider guide to coding the diagnosis and treatment of diabetes

Methylnaltrexone Bromide (Relistor)

Texas Prior Authorization Program Clinical Criteria

Provider Bulletin December 2018 Coding spotlight: diabetes provider guide to coding the diagnosis and treatment of diabetes

revolutionehr.com 2019 Clinical Quality Measure Scoring Guide

Sample. V18.2 Special Report: Postpartum Readmissions What Drives Your Rate?

Asthma J45.20 Mild, uncomplicated J45.21 Mild, with (acute) exacerbation J45.22 Mild, with status asthmaticus

Contractor Information. LCD Information. Local Coverage Determination (LCD): HOMOCYSTeine Level, Serum (L34419) Document Information

Texas Prior Authorization Program Clinical Edit Criteria. H.P. Acthar

COMPREHENSIVE DIABETES CARE

Medical Policy Original Effective Date: April 1999 Revised Date: 07/25/2018 Page 1 of 36

Texas Prior Authorization Program Clinical Edit Criteria

Fee for Service Pay for Performance Program Guidelines Program Year

Injectable Agents for the Treatment of Pulmonary Arterial Hypertension (PAH)

2017 Clinical Quality Measures

Medical Policy Routine Foot Care and Debridement of Toenails

Agents for the Treatment of Hepatitis C

Diclofenac 3% Gel, Diclofenac 1.5% and 2% Topical Solution

Drug Effectiveness Review Project Summary Report Long acting Insulins

Prior Authorization Neurontin (gabapentin) 2016

Expanded Fall Risk Factors, Locations of Data Extraction, and Coding. Diastolic blood pressure value (mmhg) Calculated body mass index

Texas Prior Authorization Program Clinical Criteria

Medical Policy Original Effective Date: Revised Date: Page 1 of 23

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Retirement Date N/A

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Texas Prior Authorization Program Clinical Criteria

Accepted. Original Article. I-Ting Liu 1, Ru-Yi Huang 1,2, Cheuk-Kwan Sun 3,4,Chi-Wei Lin 1,2

Texas Prior Authorization Program Clinical Edit Criteria

Texas Prior Authorization Program Clinical Edit Criteria

Texas Prior Authorization Program Clinical Criteria. This criteria was recommended for review by an MCO to ensure appropriate and safe utilization.

Diabetes Mellitus. and coding the complications that can occur

Diabetic Complications: Diagnosis, Documentation, Coding, and Compliance

Texas Prior Authorization Program Clinical Edit Criteria

New Drug Evaluation: Insulin degludec/aspart, subcutaneous injection

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

DIABETES CODING AND DOCUMENTATION COMPLIANCE

2 Master the ICD 10 Payment System to Prevent Revenue Losses

Learning Objectives. Novant Health. Novant Health Ambulatory CDI: How We ve Grown!

Contractor Information. LCD Information. FUTURE Local Coverage Determination (LCD): Routine Foot Care (L35138) Document Information

Insulin Prior Authorization with optional Quantity Limit Program Summary

3/20/2017. CONNECTING THE LATEST GUIDANCE FY2017 FOR ICD-10 MATTERS Kyla D. Harrison, RN, BSN, HCS-D, COS-C Visiting Nurse Association of Kansas City

Agenda. American Diabetes Association Diabetic Complications Diabetes Coding Guidelines & ICD-10 Codes Documentation

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY

ICD-10-CM: The Sage Continues

Continuous Glucose Monitoring (CGM)

Chapter. CPT only copyright 2008 American Medical Association. All rights reserved. 15Diabetic Equipment and Supplies

CLINICAL MEDICAL POLICY

Thyroid Testing

Optum360 Learning: Detailed Instruction for Appropriate ICD-10-CM Coding

Texas Prior Authorization Program Clinical Criteria. Allergen Extracts

Basal Insulin Drug Class Prior Authorization Protocol

Flexeril/Amrix (Cyclobenzaprine)

We know these take time to gather, so please plan ahead!

ICD-10. An Introduction

Clinical Policy Title: Artificial pancreas device system

Diabetic Equipment and Supplies

Supplementary Appendix Contents Table A1 Read Code List for Diabetes Mellitus 2

Professional CGM Reimbursement Guide

To be considered medically necessary, an eligible provider must prescribe all orthotics.

Agents for Cystic Fibrosis

Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone

Frequently Used Tests & ICD-10 Codes

CLINICAL MEDICAL POLICY

FY 2011 WISEWOMAN Approved ICD-9 Code List

CLINICAL MEDICAL POLICY

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Jurisdiction Oregon. Retirement Date N/A

ADMELOG, NOVOLIN, NOVOLOG, and FIASP

ClinicalTrials.gov Identifier: sanofi-aventis. Sponsor/company:

Professional CGM Reimbursement Guide

Fentanyl Agents Clinical Edit Criteria

GLUCOSE TESTING-BLOOD

Revenue Cycle Solutions Consulting & Management Services Why Words Matter Through an Endocrinology Lens 2015 The Advisory Board Company advisory.

CONTINUOUS GLUCOSE MONITORING AND INSULIN DELIVERY FOR MANAGING DIABETES

Drug Use Criteria: Exogenous Insulin Products

Cardiometabolic Indicators Documentation

Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical criteria

Risk Adjustment Documentation & Coding Improvement Reference Information for 2017

Insulin Prior Authorization Criteria For Individuals Who Purchased BlueCare/KS Solutions/EPO Products

Insulin Prior Authorization Criteria For Individuals who Purchased BlueCare / KS Solutions products

1/3/2008. Karen Burke Priscilla LeMone Elaine Mohn-Brown. Medical-Surgical Nursing Care, 2e Karen Burke, Priscilla LeMone, and Elaine Mohn-Brown

Transcription:

Texas Prior Authorization Program PDL Edit Criteria Drug/Drug Class Hypoglycemics, Lantus Insulin Information Included in this Document Hypoglycemics, Lantus Insulin Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical edit Prior authorization criteria logic: a description of how the prior authorization request will be evaluated against the clinical edit criteria rules Logic diagram: a visual depiction of the clinical edit criteria logic Supporting tables: a collection of information associated with the steps within the criteria (diagnosis codes, procedure codes, and therapy codes); provided when applicable References: clinical publications and sources relevant to this clinical edit Note: Click the hyperlink to navigate directly to that section. Revision Notes Lantus insulin moved from non-preferred status to preferred status. Edit removed. 03/26/2015 Copyright 2014-15 Health Information Designs, LLC 1

Drugs Requiring Prior Authorization Lantus Insulin Label Name GCN LANTUS 100 UNITS/ML VIAL 13072 LANTUS SOLOSTAR 100 UNITS/ML 98637 03/26/2015 Copyright 2014-15 Health Information Designs, LLC 2

PDL Edit Criteria Logic 1. Is the client less than (<) 18 years of age? [ ] Yes (Go to #2) [ ] No (Go to #3) 2. Does the client have a diagnosis of type I diabetes in the last 730 days? [ ] Yes (Approve 365 days) [ ] No (Go to #3) 3. Has the client failed a 30-day treatment trial with at least 1 preferred agent within the past 180 days? [ ] Yes (Approve 365 days) [ ] No (Go to #4) 4. Is there a documented allergy or contraindication to preferred agents in this class? [ ] Yes (Approve 365 days) [ ] No (Deny) 03/26/2015 Copyright 2014-15 Health Information Designs, LLC 3

PDL Edit Criteria Logic Diagram Step 1 Step 2 Is the client less than 18 years of age? Yes Does the client have a diagnosis of type I diabetes in the last 730 days? Yes Approve Request (365 days) No No Step 3 Has the client failed a 30-day treatment trial with at least 1 preferred agent within the past 180 days? Yes Approve Request (365 days) No Step 4 Is there a documented allergy or contraindication to preferred agents in this class? Yes Approve Request (365 days) No Deny Request 03/26/2015 Copyright 2014-15 Health Information Designs, LLC 4

PDL Edit Criteria Supporting Tables ICD-9 Code Description Step 2 (diagnosis of type I diabetes) Required quantity: 1 Look back timeframe: 730 days 25001 DIABETES MELLITUS W/O MENTION OF COMPLICATION, TYPE 1 [JUVENILE TYPE], NOT STATED AS UNCONTROLLED 25003 DIABETES MELLITUS W/O MENTION OF COMPLICATION, TYPE 1 [JUVENILE TYPE], UNCONTROLLED 25011 DIABETES WITH KETOACIDOSIS, TYPE I [JUVENILE TYPE], NOT STATED AS UNCONTROLLED 25013 DIABETES WITH KETOACIDOSIS, TYPE I [JUVENILE TYPE], UNCONTROLLED 25021 DIABETES WITH HYPEROSMOLARITY, TYPE 1 [JUVENILE TYPE], NOT STATED AS UNCONTROLLED 25023 DIABETES WITH HYPEROSMOLARITY, TYPE 1 [JUVENILE TYPE], UNCONTROLLED 25031 DIABETES WITH OTHER COMA, TYPE 1 [JUVENILE TYPE], NOT STATED AS UNCONTROLLED 25033 DIABETES WITH OTHER COMA, TYPE 1 [JUVENILE TYPE], UNCONTROLLED 25041 DIABETES WITH RENAL MANIFESTATIONS, TYPE 1 [JUVENILE TYPE], NOT STATED AS UNCONTROLLED 25043 DIABETES WITH RENAL MANIFESTATIONS, TYPE 1 [JUVENILE TYPE], UNCONTROLLED 25051 DIABETES WITH OPHTHALMIC MANIFESTATIONS, TYPE 1 [JUVENILE TYPE], NOT STATED AS UNCONTROLLED 25053 DIABETES WITH OPHTHALMIC MANIFESTATIONS, TYPE 1 [JUVENILE TYPE], UNCONTROLLED 25061 DIABETES WITH NEUROLOGICAL MANIFESTATIONS, TYPE 1 [JUVENILE TYPE], NOT STATED AS UNCONTROLLED 25063 DIABETES WITH NEUROLOGICAL MANIFESTATIONS, TYPE 1 [JUVENILE TYPE], UNCONTROLLED 25071 DIABETES WITH PERIPHERAL CIRCULATORY DISORDERS, TYPE 1 [JUVENILE TYPE], NOT STATED AS UNCONTROLLED 25073 DIABETES WITH PERIIPHERAL CIRCULATORY DISORDERS, TYPE 1 [JUVENILE TYPE], UNCONTROLLED 25081 DIABETES WITH OTHER SPECIFIED MANIFESTATIONS, TYPE 1 [JUVENILE TYPE], NOT STATED AS UNCONTROLLED 25083 DIABETES WITH OTHER SPECIFIED MANIFESTATIONS, TYPE 1 [JUVENILE TYPE], UNCONTROLLED 25091 DIABETES WITH UNSPECIFIED COMPLICATION, TYPE 1 [JUVENILE TYPE], NOT STATED AS UNCONTROLLED 03/26/2015 Copyright 2014-15 Health Information Designs, LLC 5

ICD-9 Code Description Step 2 (diagnosis of type I diabetes) Required quantity: 1 Look back timeframe: 730 days 25093 DIABETES WITH UNSPECIFIED COMPLICATION, TYPE 1 [JUVENILE TYPE], UNCONTROLLED ICD-10 Code E10 Description TYPE 1 DIABETES MELLITUS E10.1 TYPE 1 DIABETES MELLITUS WITH KETOACIDOSIS E10.10 TYPE 1 DIABETES MELLITUS WITH KETOACIDOSIS, WITHOUT COMA E10.11 TYPE 1 DIABETES MELLITUS WITH KETOACIDOSIS, WITH COMA E10.2 TYPE 1 DIABETES MELLITUS WITH KIDNEY COMPLICATIONS E10.21 TYPE 1 DIABETES MELLITUS WITH DIABETIC NEPHROPATHY E10.22 TYPE 1 DIABETES MELLITUS WITH DIABETIC CHRONIC KIDNEY DISEASE E10.29 TYPE 1 DIABETES MELLITUS WITH OTHER DIABETIC KIDNEY COMPLICATION E10.3 TYPE 1 DIABETES MELLITUS WITH OPHTHALMIC COMPLICATIONS E10.31 TYPE 1 DIABETES MELLITUS WITH UNSPECIFIED DIABETIC RETINOPATHY E10.311 TYPE 1 DIABETES MELLITUS WITH UNSPECIFIED DIABETIC RETINOPATHY WITH MACULAR EDEMA E10.319 TYPE 1 DIABETES MELLITUS WITH UNSPECIFIED DIABETIC RETINOPATHY WITHOUT MACULAR EDEMA E10.32 TYPE 1 DIABETES MELLITUS WITH MILD NONPROLIFERATIVE DIABETIC RETINOPATHY E10.321 TYPE 1 DIABETES MELLITUS WITH MILD NONPROLIFERATIVE DIABETIC RETINOPATHY WITH MACULAR EDEMA E10.329 TYPE 1 DIABETES MELLITUS WITH MILD NONPROLIFERATIVE DIABETIC RETINOPATHY WITHOUT MACULAR EDEMA E10.33 TYPE 1 DIABETES MELLITUS WITH MODERATE NONPROLIFERATIVE DIABETIC RETINOPATHY E10.331 TYPE 1 DIABETES MELLITUS WITH MODERATE NONPROLIFERATIVE DIABETIC RETINOPATHY WITH MACULAR EDEMA E10.339 TYPE 1 DIABETES MELLITUS WITH MODERATE NONPROLIFERATIVE DIABETIC RETINOPATHY WITHOUT MACULAR EDEMA E10.34 TYPE 1 DIABETES MELLITUS WITH SEVERE NONPROLIFERATIVE DIABETIC RETINOPATHY E10.341 TYPE 1 DIABETES MELLITUS WITH SEVERE NONPROLIFERATIVE DIABETIC RETINOPATHY WITH MACULAR EDEMA E10.349 TYPE 1 DIABETES MELLITUS WITH SEVERE NONPROLIFERATIVE DIABETIC RETINOPATHY WITHOUT MACULAR EDEMA E10.35 TYPE 1 DIABETES MELLITUS WITH PROLIFERATIVE DIABETIC RETINOPATHY E10.351 TYPE 1 DIABETES MELLITUS WITH PROLIFERATIVE DIABETIC RETINOPATHY WITH MACULAR EDEMA E10.359 TYPE 1 DIABETES MELLITUS WITH PROLIFERATIVE DIABETIC RETINOPATHY WITHOUT MACULAR EDEMA E10.36 TYPE 1 DIABETES MELLITUS WITH DIABETIC CATARACT E10.39 TYPE 1 DIABETES MELLITUS WITH OTHER DIABETIC OPHTHALMIC COMPLICATION 03/26/2015 Copyright 2014-15 Health Information Designs, LLC 6

ICD-10 Code Description Step 2 (diagnosis of type I diabetes) Required quantity: 1 Look back timeframe: 730 days E10.4 TYPE 1 DIABETES MELLITUS WITH NEUROLOGICAL COMPLICATION E10.40 TYPE 1 DIABETES MELLITUS WITH DIABETIC NEUROPATHY, UNSPECIFIED E10.41 TYPE 1 DIABETES MELLITUS WITH DIABETIC MONONEUROPATHY E10.42 TYPE 1 DIABETES MELLITUS WITH DIABETIC POLYNEUROPATHY E10.43 TYPE 1 DIABETES MELLITUS WITH DIABETIC AUTONOMIC (POLY)NEUROPATHY E10.44 TYPE 1 DIABETES MELLITUS WITH DIABETIC AMYOTROPHY E10.49 TYPE 1 DIABETES MELLITUS WITH OTHER DIABETIC NEUROLOGICAL COMPLICATION E10.5 TYPE 1 DIABETES MELLITUS WITH CIRCULATORY COMPLICATIONS E10.51 TYPE 1 DIABETES MELLITUS WITH DIABETIC PERIPHERAL ANGIOPATHY WITHOUT GANGRENE E10.52 TYPE 1 DIABETES MELLITUS WITH DIABETIC PERIPHERAL ANGIOPATHY WITH GANGRENE E10.59 TYPE 1 DIABETES MELLITUS WITH OTHER CIRCULATORY COMPLICATIONS E10.6 TYPE 1 DIABETES MELLITUS WITH OTHER SPECIFIED COMPLICATIONS E10.61 TYPE 1 DIABETES MELLITUS WITH DIABETIC ARHROPATHY E10.610 TYPE 1 DIABETES MELLITUS WITH DIABETIC NEUROPATHIC ARTHROPATHY E10.618 TYPE 1 DIABETES MELLITUS WITH OTHER DIABETIC ARTHROPATHY E10.62 TYPE 1 DIABETES MELLITUS WITH SKIN COMPLICATION E10.620 TYPE 1 DIABETES MELLITUS WITH DIABETIC DERMATITIS E10.621 TYPE 1 DIABETES MELLITUS WITH FOOT ULCER E10.622 TYPE 1 DIABETES MELLITUS WITH OTHER SKIN ULCER E10.628 TYPE 1 DIABETES MELLITUS WITH OTHER SKIN COMPLICATIONS E10.63 TYPE 1 DIABETES MELLITUS WITH ORAL COMPLICATIONS E10.630 TYPE 1 DIABETES MELLITUS WITH PERIODONTAL DISEASE E10.638 TYPE 1 DIABETES MELLITUS WITH OTHER ORAL COMPLICATIONS E10.64 TYPE 1 DIABETES MELLITUS WITH HYPOGLYCEMIA E10.641 TYPE 1 DIABETES MELLITUS WITH HYPOGLYCEMIA WITH COMA E10.649 TYPE 1 DIABETES MELLITUS WITH HYPOGLYCEMIA WITHOUT COMA E10.65 TYPE 1 DIABETES MELLITUS WITH HYPERGLYCEMIA E10.69 TYPE 1 DIABETES MELLITUS WITH OTHER SPECIFIED COMPLICATION E10.8 TYPE 1 DIABETES MELLITUS WITH UNSPECIFIED COMPLICATIONS E10.9 TYPE 1 DIABETES MELLITUS WITHOUT COMPLICATIONS 03/26/2015 Copyright 2014-15 Health Information Designs, LLC 7

Step 3 (alternate therapy) Required quantity: 1 Look back timeframe: 180 days Label Name GCN HUM INSULIN NPH/REG INSULIN HM 24486 HUM INSULIN NPH/REG INSULIN HM 50001 HUM INSULIN NPH/REG INSULIN HM 50101 HUM INSULIN NPH/REG INSULIN HUM 00890 INSULIN ASP PRT/IINSULIN ASPART 19057 INSULIN ASP PRT/INSULIN ASPART 17074 INSULIN ASP PRT/INSULIN ASPART 17074 INSULIN ASPART 92326 INSULIN ASPART 92336 INSULIN ASPART 92886 INSULIN DETEMIR 22836 INSULIN DETEMIR 25305 INSULIN LISPRO 05679 INSULIN NPL/INSULIN LISPRO 22681 INSULIN NPL/INSULIN LISPRO 97507 INSULIN REGULAR, HUMAN 05473 INSULIN REGULAR, HUMAN 09631 INSULIN REGULAR, HUMAN 09633 INSULIN REGULAR, HUMAN 11642 INSULIN REGULAR, HUMAN 15518 INSULIN ZINC HUMAN REG 05720 NPH, HUMAN INSULIN ISOPHANE 05331 NPH, HUMAN INSULIN ISOPHANE 11660 NPH, HUMAN INSULIN ISOPHANE 18488 03/26/2015 Copyright 2014-15 Health Information Designs, LLC 8

PDL Edit Criteria References 1. Clinical Pharmacology [online database]. Tampa, FL: Elsevier / Gold Standard, Inc.; 2014. Available at http://www.clinicalpharmacology.com. Accessed on April 17, 2014. 2. 2014 ICD-9-CM Diagnosis Codes, Volume 1. 2013. Available at http://www.icd9data.com/. Accessed on April 17, 2014. 3. 2014 ICD-10-CM Diagnosis Codes, Volume 1. 2013. Available at http://www.icd9data.com/. Accessed on April 17, 2014. 4. Lantus prescribing information. Bridgewater, NJ: Sanofi-Aventis U.S. LLC. December 2013. 03/26/2015 Copyright 2014-15 Health Information Designs, LLC 9

Publication History The Publication History records the publication iterations and revisions to this document. Notes for the most current revision are also provided in the Revision Notes on the first page of this document. Publication Date Notes 05/01/2014 Initial publication and posting on website. 01/22/2015 Lantus moved from non-preferred status to preferred status. Edit removed. 03/26/2015 Lantus no longer requires a PDL edit. Guide removed from website. 03/26/2015 Copyright 2014-15 Health Information Designs, LLC 10